Friday, 21 Feb 2020

Drug Safety

Datesort ascending Type Title Save
12 Aug 2019 Slide of the day CANTOS vs. CIRT Trial Comparison
09 Aug 2019 News NSAIDs Mediate Cardiovascular Risk in OA
05 Aug 2019 Social Claims analysis of f 45,208 TNFi +MTX initiators and 1,387 triple DMARD (MSH) initiators showed no significant difference in the risk of serious infections (2.46 TNFi+MTX vs 2.03 triple DMARD/100PY) (HR 1.23; 0.87‐1.74) https://t.co/pe52p8Xtrv
29 Jul 2019 Social Testosterone replacement therapy Increases the risk of CV events (MI/CVA/TIA). Study of 15,401 men, >45 yrs old, w/ low testosterone & no evidence of hypogonadotropic or testicular dz (1995-2017). HR 1.21; CI 1.0-1.46), highest in the 1st 2yrs https://t.co/nNXyFIo1EH
28 Jul 2019 Social Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a negative opinion on Application for romosozumab (Evenity) for the treatment of severe osteoporosis (by Amgen & UCB); an appeal is planned https://t.co/EVjxuBQdF0
26 Jul 2019 Social The RheumNow Podcast is up! News, Announcements of generics/biosimilars, approvals and FDA hearings. Watch the video here>> https://t.co/3tW7uRivgQ or listen to the podcast on iTunes>> https://t.co/q2bscJkIhs
26 Jul 2019 Social RT @RheumNow: The FDA Arthritis Advisory Committee has voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib f…
26 Jul 2019 Social FDA puts a New Boxed Warning on #tofacitinib for Blood Clots and Death with Higher Doses (10 mg bid). https://t.co/Bzgst3ooo0
26 Jul 2019 News Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses
25 Jul 2019 Social The FDA Arthritis Advisory Committee has voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
25 Jul 2019 Social FDA warning about meds that may impair driving (car, bus, train, plane, or boat) - Especially opioids, benzodiazepines, antidepressants, muscle relaxants, sleep meds, motion sickness & diet pills, ADD or “stay awake” drugs https://t.co/P08wvds0GK
18 Jul 2019 Social anti-MDA5+ amyopathic dermatomyositis (ADM) with ILD is severe and refractory. NEJM letter reports on 18 ADM Rx w/ tofacitinibs who showed better 6 mo survival (100% vs 78%) (P=0.04) and improved ferritin, FVC, DLCO, & CT Chest over time. https://t.co/lsVGPxChoO
18 Jul 2019 Social Can Febuxostat be given to Allopurinol Hypersensitivity? Such pts not included in registrations trials; yet many literature reports of no toxicity & rare cross-Rxn; PI says ULORIC indicated w/ intolerant to allopurinol, or when allopurinol Tx not advisable https://t.co/KG36Ls6VsI
10 Jul 2019 News EHR-Related Adverse Events Usually Involve Medications
10 Jul 2019 Social CBD isn't entirely safe. Forbes reviews evidence of hepatotoxicity, esp with the CBD-based epilepsy drug Epidiolex; in studies 5-20% had liver issues. FDA has also warned of suicidal ideation, agitation, suicide, depression, aggression & panic attacks https://t.co/I83QVXwsl6
09 Jul 2019 Social Metanalysis of 277 RCTs &1 million evaluated 16 nutritional supplements & 8 dietary interventions showed largely no effect on mortality and CV outcomes in adults. There was evidence favoring reduced salt & omega-3, long-chain fatty acids. https://t.co/sojx842jLt
09 Jul 2019 Social RTX product label list these postmarketing AEs (not seen in trials) - uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, and vasculitis with rash. https://t.co/kpr699j2wQ
05 Jul 2019 Social RT @RheumNow: Dr. Kevin Winthrop - Expert Advice on TB Testing and Treatment from #EULAR2019 https://t.co/Nz7oKiIjrm
28 Jun 2019 Social RheumNow Podcast is UP! Discussions of MTX stomatitis, Loading doses, PPD Shortage, infection risk from steroids or THR/TKR and more. Watch it here>> https://t.co/8koj2HG4RC or listen in on iTunes or SoundCloud >> https://t.co/0EXaXq2l7G
27 Jun 2019 Social Metanalysis of 3954 studies, 20 RCTs examined MTX toxicity and found the prevalence of alopecia to be 1- 4.9% and the prevalence of stomatitis to be between 5.7-8% https://t.co/LHbAYvV71X